Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc (MNPR) is a clinical-stage biopharmaceutical company advancing targeted radiopharmaceuticals for oncology and rare diseases. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and scientific advancements.
Access comprehensive coverage of MNPR's innovative pipeline, including MNPR-101 imaging/therapeutic agents and ALXN-1840 for Wilson disease. Track progress across preclinical studies, partnership announcements, and peer-reviewed research developments.
Our curated news includes updates on uPAR-targeted therapies, clinical trial results, manufacturing partnerships, and strategic collaborations. Content is verified for accuracy and relevance to support informed analysis of MNPR's position in precision oncology.
Bookmark this page for streamlined access to Monopar's latest developments. Check regularly for updates on therapeutic candidates, regulatory filings, and scientific publications driving innovation in radiopharmaceutical cancer treatments.
Monopar Therapeutics (Nasdaq: MNPR) has enrolled the first patient in its first-in-human Phase 1 trial for MNPR-101-Zr, a novel radiopharmaceutical imaging agent. This agent combines Monopar's antibody, MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR) with the radioisotope zirconium-89. The trial, led by Prof. Rodney Hicks at the Melbourne Theranostic Innovation Centre, aims to assess the safety and dosimetry in up to 12 patients with advanced cancers. uPAR is a target in aggressive cancers such as pancreatic, triple-negative breast, and colorectal cancers. Preclinical results have been promising.
Monopar Therapeutics (Nasdaq: MNPR) has announced that their abstract on MNPR-101-RIT has been selected as a top-rated oral presentation at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress in Hamburg, Germany. The abstract showcases preclinical data on MNPR-101-RIT, a novel radio-immuno-therapeutic targeting urokinase plasminogen activator receptor (uPAR) for treating cancers such as triple-negative breast, colorectal, and pancreatic. The data highlights significant anti-tumor benefits using therapeutic radioisotopes Lutetium-177 and Actinium-225. Additionally, Monopar has started a Phase 1 clinical trial for MNPR-101-Zr in advanced cancer patients.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes have expanded their collaboration to include a long-term supply agreement for actinium-225 (Ac-225). This strategic move aligns intellectual property rights and leverages NorthStar's expertise in Ac-225 production with Monopar's promising preclinical results using Ac-225 in its MNPR-101 radiopharma program. Monopar has acquired full ownership of MNPR-101's radiopharmaceutical applications, while both companies will share a patent application for a new linker technology. This collaboration aims to support Monopar's current and future cancer therapy developments.
Monopar Therapeutics (Nasdaq: MNPR) is presenting data on its lead radiopharma program MNPR-101-Zr at the 2024 SNMMI Annual Meeting. The data demonstrates the potential of urokinase plasminogen activator receptor (uPAR) as a target for radiopharma cancer treatment. In preclinical trials on mice with human tumor xenografts, MNPR-101-Zr showed strong and durable tumor uptake in triple-negative breast, colorectal, and pancreatic cancers, with minimal accumulation in bone and healthy tissues. Monopar has started a Phase 1 clinical trial for MNPR-101-Zr in advanced cancer patients, led by Prof. Rodney Hicks. The trial details are available under study identifier NCT06337084.
Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company, announced the retirement of CFO Kim R. Tsuchimoto after a 35-year career. Her last day will be June 30, 2024, but she will stay on the Board of Directors. Karthik Radhakrishnan, with over 20 years of financial experience, will succeed her starting July 1, 2024. Radhakrishnan's background includes roles as CFO of Santalis Pharmaceuticals and CEO of Asylia Therapeutics. CEO Chandler Robinson acknowledged Tsuchimoto's contributions and expressed enthusiasm for Radhakrishnan's appointment, highlighting his consulting work with Monopar over the past six months.
Monopar Therapeutics Inc. reported its first-quarter 2024 financial results and a strategic focus on its radiopharma pipeline. The company initiated the MNPR-101-Zr Phase 1 clinical trial and aims to launch the MNPR-101-RIT Phase 1 trial by Q4 2024 or Q1 2025. Monopar is winding down non-radiopharma programs to concentrate resources on radiopharma assets. The company is well-funded till at least June 30, 2025, with a net loss of $1.6 million for Q1 2024. R&D expenses decreased, while G&A expenses saw a slight drop.
FAQ
What is the current stock price of Monopar Therapeutics (MNPR)?
What is the market cap of Monopar Therapeutics (MNPR)?
